Phaseline

Targets › RXRG

RXRG (Retinoic acid receptor RXR-gamma): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Mar 2027.

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. (UniProt, P48443)

Open in Phaseline: the race on RXRG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Hospital Medical Center, CincinnatiVitamin A
Retinoid receptor ligand; immunomodulatory effects on T cell differentiation and GVHD
RXRA, RXRB, RXRG, RARA, RARBPhase 2Graft Vs Host DiseaseAug 2027
Memorial Sloan Kettering Cancer CenterBexarotene
Retinoid X receptor agonist
RXRB, RXRG, RXRAPhase 1Cutaneous T-cell LymphomaMar 2027
SciTech DevelopmentST-001 nanoFenretinide (Fenretinide)
Retinoid X receptor (RXR) agonist; pro-apoptotic retinoid with activity in lymphomas
RXRA, RXRB, RXRGPhase 1Small Cell Lung Cancer; T-cell LymphomaMay 2027
The Methodist Hospital Research InstituteAll-Trans Retinoic Acid (ATRA)
Retinoid acid receptor (RAR/RXR) agonist
RXRA, RXRB, RXRGPhase 1Multiple MyelomaJul 2029

Conditions

Cutaneous T-cell Lymphoma (1) Small Cell Lung Cancer (1) T-cell Lymphoma (1) Multiple Myeloma (1) Graft Vs Host Disease (1)

Modalities

small molecule (4)

Companies

Memorial Sloan Kettering Cancer Center (1) SciTech Development (1) The Methodist Hospital Research Institute (1) Children's Hospital Medical Center, Cincinnati (1)

Related targets

RXRB (4) RXRA (4) RARA (1) RARB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.